BRAF V600E mutation positive+1
RecruitingStudy on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations
Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations
- Disease:BRAF V600E mutation positiveBRAF gene mutation
- Substances:Cobicistat(3R)-N-[3-[5-(2-Cyclopropylpyrimidin-5-Yl)-1H-Pyrrolo[2,3-B]Pyridine-3-Carbonyl]-2,4-Difluorophenyl]-3-Fluoropyrrolidine-1-Sulfonamide
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Cobicistat
- Sponsor:Fore Biotherapeutics Inc.











